Advertisement
Screener

GENELUX CORPORATION (GNLX) Graph

GNLX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $6.51M; Operating expenses $9.64M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $5.78M; Operating expenses $9.17M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development $5.65M*; Operating expenses $9.42M*; Income tax (m).
  • 2025-09-30: Revenue (m); Research and development $4.74M; Operating expenses $8.19M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$6.51M$9.64M(m)-$9.47M
2026-03-31(m)$5.78M$9.17M(m)-$8.93M
2025-12-31(m)$5.65M*$9.42M*(m)-$9.25M*
2025-09-30(m)$4.74M$8.19M(m)-$7.95M
2025-06-30(m)$4.76M$7.79M(m)-$7.46M
2025-03-31(m)$4.70M$7.82M(m)-$7.49M
2024-09-30(m)$4.05M$6.94M(m)-$6.47M
2024-06-30(m)$4.42M$6.89M(m)-$6.58M
2024-03-31$8.00K$4.01M$8.12M(m)-$7.85M
2023-09-30(m)$2.82M$5.31M(m)-$5.34M
2023-06-30(m)$2.94M$5.39M(m)-$5.82M
2023-03-31$170.00K$2.85M$6.63M(m)-$10.36M
2022-09-30$11.00M$2.41M$4.66M$1.10M$4.91M
2022-06-30(m)$1.83M$2.80M(m)-$2.82M
2022-03-31(m)$2.37M$3.46M(m)-$3.80M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$12.29M$18.82M-$18.40M
2025-06-30(m)$9.46M$15.61M-$14.95M
2024-06-30$8.00K$8.43M$15.02M-$14.43M
2023-06-30$170.00K$5.79M$12.03M-$16.18M
2022-06-30(m)$4.20M$6.26M-$6.62M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$14.20M$23.80M(m)-$22.90M
2024-09-30$8.00K$12.48M$21.96M(m)-$20.89M
2023-09-30$170.00K$8.61M$17.33M(m)-$21.53M
2022-09-30$11.00M$6.61M$10.92M$1.10M-$1.71M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$8.00K$19.85M$33.22M(m)-$32.15M
2024-12-31$8.00K$19.00M$31.70M(m)-$29.87M
2023-12-31$170.00K$12.77M$24.34M(m)-$28.30M
2022-12-31$11.07M$9.08M$14.08M$1.10M-$5.21M

Similar stocks

Stock NameCountryMarket CapPE Ratio
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Equillium, Inc. (EQ)United States$0.109B-11.27
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95